Americas Insomnia Market Summary
The United States insomnia market is projected to grow from 2.43 USD billion in 2024 to 4.12 USD billion by 2035.
Key Market Trends & Highlights
Americas Insomnia Key Trends and Highlights
- The insomnia market in the United States is expected to experience a compound annual growth rate of 5.34 percent from 2025 to 2035.
- By 2035, the market valuation is anticipated to reach 4.31 USD billion, indicating robust growth potential.
- in 2024, the market is valued at 2.43 USD billion, reflecting the current demand for insomnia solutions.
- Growing adoption of innovative sleep therapies due to increasing awareness of mental health is a major market driver.
Market Size & Forecast
2024 Market Size | 2.43 (USD Billion) |
2035 Market Size | 4.12 (USD Billion) |
CAGR (2025-2035) | 4.92% |
Major Players
Eisai, Co. (Japan), Pfizer, Inc. (US), Merck & Co Inc (US), Sanofi (France), Takeda Pharmaceutical Company (Japan), Meda Consumer Healthcare Inc (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Consumer Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), Flynn Pharma (UK), Johnson & Johnson (US), Astellas (UK), Biocodex S A (France), Neurim (Switzerland), SkyePharma (UK), Vanda Pharmaceuticals Inc. (US)